RxDoctor Payments Data

Andrew Shreiner, MD

Gastroenterology · Grand Rapids, MINPI 1437461639

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.9% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Olympus America Inc. at 45.9% of the total. Reporting peaked in 2022 at $301 and has fallen 58.5% since, to $125 in 2025. That places this record below the midpoint for gastroenterology clinicians in MI, where the typical reported total is $1,620.

$772in general payments, 2019–2025

Across 21 payments — averaging $36.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$355
  • Medtronic$165
  • Takeda Pharmaceuticals U.S.A., Inc.$108
  • Madrigal Pharmaceuticals$50
  • AbbVie$42
  • Pfizer$21
  • plus $31 from 2 others
$64,137in research payments, 2019–2025

Across 13 payments — averaging $4933.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$64K

What the payments were for

  • Food & beverage$71793%
  • Education$557%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$772 in reported general payments places this provider in the 40th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$37,489
Medicare patients
185
Services billed
335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab25$235,120
Mesalamine21$10,575
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg190$4,639
Budesonide DrBudesonide29$2,832
Omeprazole155$2,610
Budesonide EcBudesonide17$1,978
Azathioprine29$1,916
SutabSod Sulf/Pot Chloride/Mag Sulf12$1,909
Pantoprazole Sodium36$647
Lansoprazole15$440
Famotidine27$417
Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg13$243
Prednisone16$168
Ondansetron OdtOndansetron11$118

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →